These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 18954673)

  • 1. Aprotinin and renal dysfunction: the role of exposure to angiotensin-converting enzyme inhibitors.
    Augoustides JG
    J Thorac Cardiovasc Surg; 2008 Oct; 136(4):1104; author reply 1104. PubMed ID: 18954673
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of aprotinin on renal dysfunction in patients undergoing on-pump and off-pump cardiac surgery: a retrospective observational study.
    Mouton R; Finch D; Davies I; Binks A; Zacharowski K
    Lancet; 2008 Feb; 371(9611):475-82. PubMed ID: 18262039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin-converting enzyme inhibitors and risk of acute kidney injury after cardiac surgery.
    Bouzas-Mosquera A; Alvarez-García N; Peteiro J
    Ann Thorac Surg; 2009 May; 87(5):1653; author reply 1653-4. PubMed ID: 19379947
    [No Abstract]   [Full Text] [Related]  

  • 4. The association of renal dysfunction and the use of aprotinin in patients undergoing congenital cardiac surgery requiring cardiopulmonary bypass.
    Manrique A; Jooste EH; Kuch BA; Lichtenstein SE; Morell V; Munoz R; Ellis D; Davis PJ
    Anesth Analg; 2009 Jul; 109(1):45-52. PubMed ID: 19535694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary prevention after coronary artery bypass grafting--what do we know?
    Herlitz J
    Scand Cardiovasc J; 2004 May; 38(2):69-74. PubMed ID: 15204230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Letter by Augoustides regarding article, "Risk index for perioperative renal dysfunction/failure: critical dependence on pulse pressure hypertension".
    Augoustides JG
    Circulation; 2007 Jul; 116(5):e119; author reply e120. PubMed ID: 17664381
    [No Abstract]   [Full Text] [Related]  

  • 7. Invited commentary.
    Stafford-Smith M
    Ann Thorac Surg; 2008 Oct; 86(4):1165-6. PubMed ID: 18805153
    [No Abstract]   [Full Text] [Related]  

  • 8. Postoperative renal failure after aprotinin infusion and spine operations.
    Nielsen CH
    Anesth Analg; 2006 Oct; 103(4):1062-3. PubMed ID: 17000859
    [No Abstract]   [Full Text] [Related]  

  • 9. Does the combination of aprotinin and angiotensin-converting enzyme inhibitor cause renal failure after cardiac surgery?
    Royston D
    Ann Thorac Surg; 2006 Oct; 82(4):1575; author reply 1575-6. PubMed ID: 16996997
    [No Abstract]   [Full Text] [Related]  

  • 10. Aprotinin--still courting controversy.
    Hausenloy DJ; Pagano D; Keogh B
    Lancet; 2008 Feb; 371(9611):449-50. PubMed ID: 18262023
    [No Abstract]   [Full Text] [Related]  

  • 11. Nurses make the difference.
    Cappell MS
    Gastroenterol Nurs; 2009; 32(3):216-7. PubMed ID: 19506440
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of angiotensin-converting enzyme inhibitors in the coronary artery bypass patient.
    Lazar HL
    Ann Thorac Surg; 2005 Mar; 79(3):1081-9. PubMed ID: 15734453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of angiotensin-converting enzyme inhibitor on hemodynamic instability in patients undergoing cardiopulmonary bypass: results of a dose-comparison study.
    Shahzamani M; Yousefi Z; Frootaghe AN; Jafarimehr E; Froughi M; Tofighi F; Azadani AN; Pourhoseingholi MA; Azadani PN
    J Cardiovasc Pharmacol Ther; 2009 Sep; 14(3):185-91. PubMed ID: 19721131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of aprotinin on postoperative renal dysfunction in neonates undergoing cardiopulmonary bypass: a retrospective analysis.
    Guzzetta NA; Evans FM; Rosenberg ES; Fazlollah TM; Baker MJ; Wilson EC; Kaiser AM; Tosone SR; Miller BE
    Anesth Analg; 2009 Feb; 108(2):448-55. PubMed ID: 19151271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obesity is associated with increased morbidity after coronary artery bypass graft surgery in patients with renal insufficiency.
    Tolpin DA; Collard CD; Lee VV; Elayda MA; Pan W
    J Thorac Cardiovasc Surg; 2009 Oct; 138(4):873-9. PubMed ID: 19660351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. All coronary artery bypass graft surgery patients will benefit from angiotensin-converting enzyme inhibitors.
    Lazar HL
    Circulation; 2008 Jan; 117(1):6-8. PubMed ID: 18172046
    [No Abstract]   [Full Text] [Related]  

  • 17. Angiotensin-converting enzyme inhibitor as a marker, not a risk factor, for poor prognosis.
    Chien KL
    J Am Coll Cardiol; 2010 Mar; 55(9):930; author reply 930-1. PubMed ID: 20185048
    [No Abstract]   [Full Text] [Related]  

  • 18. Intraoperative coronary thrombosis with aprotinin in the prebypass period.
    Myles PS; Esmore DS
    J Cardiothorac Vasc Anesth; 2007 Aug; 21(4):558-60. PubMed ID: 17678784
    [No Abstract]   [Full Text] [Related]  

  • 19. The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients.
    Martin K; Wiesner G; Breuer T; Lange R; Tassani P
    Anesth Analg; 2008 Dec; 107(6):1783-90. PubMed ID: 19020118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should patients with stenosis of the left main coronary artery waiting for bypass grafting be given priority?
    Rexius H
    CMAJ; 2005 Aug; 173(4):381-2. PubMed ID: 16103511
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.